05:38 PM EDT, 03/14/2024 (MT Newswires) -- Nuvation Bio ( NUVB ) said late Thursday the first patient has been dosed in a phase 1/2 study of NUV-1511 to treat advanced solid tumors.

The company said the study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for indications of clinical activity in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu and/or Trodelvy.

Nuvation Bio ( NUVB ) shares were down 2.8% in after-hours activity.

Price: 2.13, Change: -0.06, Percent Change: -2.75